Author: Cattaneo, Marco

Source: Expert Review of Cardiovascular Therapy, Volume 5, Number 1, January 2007 , pp. 45-55(11)

Publisher: Expert Reviews

Abstract:

Platelets possess three P2 receptors for adenine nucleotides: P2Y₁ and P2Y₁₂, which interact with ADP, and P2X₁, which interacts with ATP. The interaction of adenine nucleotides with their platelet receptors plays an important role in thrombogenesis. The thienopyridine ticlopidine, an antagonist of the platelet P2Y₁₂ ADP receptor, reduces the incidence of vascular events in patients at risk, but it also has some important drawbacks: a relatively high incidence of toxic effects; delayed onset of action; high inter-individual variability in response. Another thienopyridine, clopidogrel, has superseded ticlopidine, because it is an efficacious antithrombotic drug and is less toxic than ticlopidine. However, the high inter-patient variability in response still remains an important issue. These drawbacks justify the continuing search for agents that can further improve the clinical outcome of patients with atherosclerosis through greater efficacy and/or safety. A new thienopyridyl compound prasugrel, which is characterized by higher potency and faster onset of action compared with clopidogrel, is currently under clinical evaluation. Two direct and reversible P2Y₁₂ antagonists, cangrelor and AZD6140, have very rapid onset and reversal of platelet inhibition, which make them attractive alternatives to thienopyridines, especially when rapid inhibition of platelet aggregation or its quick reversal are required. Along with new P2Y₁₂antagonists, inhibitors of the other platelet receptor for ADP, P2Y₁, and of the receptor for ATP, P2X₁, are under development and may prove to be effective antithrombotic agents.

Keywords: ADP; antiplatelet agents; ATP; clopidogrel; P2 receptors; platelets; prasugrel; thienopyridines; thrombosis; ticlopidine

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14779072.5.1.45

Publication date: 2007-01-01

More about this publication?

• Expert Review of Cardiovascular Therapy provides expert commentary on the clinical applications of the new medicines, therapeutic agents and diagnostics in cardiovascular disease. Coverage inculdes drug therapy, heart disease, vascular disorders, hypertension, cholesterol in cardiovascular disease, heart disease, stroke, heart failure and cardiovascular surgery.
• Editorial Board
• Information for Authors
• Submit a Paper
• Subscribe to this Title
• Information for Advertisers
• Terms & Conditions
• Information for Librarians
• Free Trials
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Cardiovascular Medicine ,  Pharmacology
• By this author: Cattaneo, Marco

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers